Skip to main content
SpringerLink
Log in
Book cover

Drugs Affecting Lipid Metabolism pp 333–338Cite as

Experimental and Clinical Evidence for a Protective Role of High-Density Lipoprotein in Coronary Heart Disease

  • Chapter

  • 85 Accesses

Part of the book series: Medical Science Symposia Series ((MSSS,volume 2))

Abstract

An inverse relation between high-density lipoprotein (HDL) cholesterol and the incidence and/or prevalence of coronary heart disease (CHD) has been firmly established in numerous epidemiologic studies. Data from the Framingham Heart Study, the Lipid Research Clinics (LRC) Prevalence Mortality Follow-up Study, the LRC Coronary Primary Prevention Trial, and the Multiple Risk Factor Intervention Trial have all suggested a 2% to 3% decrease in CHD risk for each 1 mg/dl (0.026 mmol/L) increase in HDL cholesterol after correction for other risk factors [1]. In man, limited information is available as to whether increasing HDL cholesterol would reduce the risk of CHD. However, animal experiments support the notion that increasing HDL may be beneficial. Infusion of HDL into rabbits fed an atherogenic diet was associated with reduced severity and extent of atherosclerotic lesions in comparison with control animals fed the same diet [2]. Similar conclusions were reached in transgenic mice in that overexpression of human apolipoprotein (apo) A-I decreased the severity of diet-induced atherosclerosis [3].

The mechanisms whereby HDL provides protection from CHD are not fully understood. The two major hypotheses, not exclusive of each other, are that certain HDL particles directly interfere with the atherogenic process, and that high levels of HDL cholesterol are indicative of a metabolic state that confers protection from CHD.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15.

    Article  PubMed  CAS  Google Scholar 

  2. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. — Clin Invest 1990;85:1234–1241.

    Article  PubMed  CAS  Google Scholar 

  3. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265–267.

    Article  PubMed  CAS  Google Scholar 

  4. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. — Lipid Res 1968;9:1551–1567.

    Google Scholar 

  5. Stein Y, Glangeaud MC, Fainaru M, Stein O. The removal of cholesterol from aortic smooth muscle cells in culture and Landschutz ascites cells by fractions of human high-density apolipoprotein. Biochim Biohys Acta 1975;380:106–118.

    Article  CAS  Google Scholar 

  6. Ho YK, Brown MS, Goldstein JL. Hydrolysis and excretion of cytoplasmic cholesteryl esters by macrophages: Stimulation by high density lipoprotein and other agents. — Lipid Res 1980;21:391–398.

    PubMed  CAS  Google Scholar 

  7. Tauber JP, Cheng J, Gospodarowicz D. Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. — Clin Invest 1980;66:696–708.

    Article  PubMed  CAS  Google Scholar 

  8. Burkey BF, Vlasic N, France D, Hughes TE, Drelich M, Ma X, Stemerman MB, Paterniti JR Jr. Elevated apolipoprotein A-I (apo A-I) pools in human apo A-I transgenic rats decrease aortic smooth muscle cell proliferation following balloon angioplasty [Abstract]. Abstracts submitted to the Council on Arteriosclerosis for the 65th Scientific Sessions of the American Heart Association, November 16-19, 1992;38. Unpublished abstracts book.

    Google Scholar 

  9. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275–283.

    Article  PubMed  CAS  Google Scholar 

  10. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (apo A-I). — novel function of apo A-I. — Clin Invest 1988;82:803–807.

    Article  PubMed  CAS  Google Scholar 

  11. Tsai AL, Hsu MJ, Patsch W, Wu KK. Regulation of PGI2 activity by serum proteins: Serum albumin but not high density lipoprotein is the PGI2 binding and stabilizing protein in human blood. Biochim Biophys Acta 1991;1115:131–140.

    Article  PubMed  CAS  Google Scholar 

  12. Breslow JL. Genetic basis of lipoprotein disorders. — Clin Invest 1989;84:373–380.

    Article  PubMed  CAS  Google Scholar 

  13. Schmitz G, Assmann G, Robenek H, Brennhausen B. Tangier disease: — disorder of intracellular membrane traffic. Proc Natl Acad Sci USA. 1985;82:6305–6309.

    Article  PubMed  CAS  Google Scholar 

  14. Patsch W, Schonfeld G, Gotto AM Jr, Patsch Jr. Characterization of human high density lipoproteins by zonal ultracentrifugation. — Biol Chem 1980;255:3178–3185.

    PubMed  CAS  Google Scholar 

  15. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. — prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. — Engl — Med 1991;325:373–381.

    Article  CAS  Google Scholar 

  16. Miller NE, Hammett F, Saltissi S, Rao S, van Zeller H, Coltart J, Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med — 1981;282:1741–1744.

    Article  CAS  Google Scholar 

  17. Breier C, Patsch JR, Muhlberger V, Drexel H, Knapp E, Braunsteiner H. Risk factors for coronary artery disease: — study comparing hypercholesterolemia and hypertriglyceridaemia in angiographically characterized patients. Eur — Clin Invest 1989;19:419–423.

    Article  CAS  Google Scholar 

  18. Nichols AV. Human serum lipoproteins and their interrelationships. Adv Biol Med Phys 1967;11:109–158.

    PubMed  CAS  Google Scholar 

  19. Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: Familial hypobeta and familial hyperalpha lipoproteinemia. — Lab Clin Med 1976;88:941–957.

    PubMed  CAS  Google Scholar 

  20. Patsch W, Kuisk I, Glueck C, Schonfeld G. Lipoproteins in familial hyperalphalipoproteinemia. Arteriosclerosis 1981;1:156–161.

    Article  PubMed  CAS  Google Scholar 

  21. Patsch JR, Gotto AM Jr, Olivecrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci USA. 1978;75:4519–4523.

    Article  PubMed  CAS  Google Scholar 

  22. Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High density lipoprotein2 Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. — Clin Invest 1987;80:341–347.

    Article  PubMed  CAS  Google Scholar 

  23. Patsch Jr, Prasad S, Gotto AM Jr, Bengtsson-Olivecrona G. Postprandial lipemia. — key for the conversion of high density lipoproteins into high density lipoprotein by hepatic lipase. — Clin Invest 1984;74:2017–2023.

    Article  PubMed  CAS  Google Scholar 

  24. Behr SR, Patsch Jr, Forte T, Bensadoun A. Plasma lipoprotein changes resulting from immunologically blocked lipolysis. — Lipid Res 1981;22:443–451.

    PubMed  CAS  Google Scholar 

  25. Ito Y, Azrolan N, O’Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as — result of human apo Oil gene expression in transgenic mice. Science 1990;249:790–793.

    Article  PubMed  CAS  Google Scholar 

  26. Whitlock ME, Swenson TL, Ramakrishnan R, Leonard MT, Marcel YL, Milne RW, Tall AR. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. — Clin Invest 1989;84:129–137.

    Article  PubMed  CAS  Google Scholar 

  27. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. — Biol Chem 1991;266:10796–10801.

    PubMed  CAS  Google Scholar 

  28. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by — common cholesteryl-ester transfer protein gene mutation. — Engl — Med 1990;323:1234–1238.

    Article  CAS  Google Scholar 

  29. Stein OJ, Vanderhoek J, Stein Y. Cholesterol content and sterol synthesis in human skin fibroblasts and rat aortic smooth muscle cells exposed to lipoprotein-depleted serum and high density apolipoprotein/phospholipid mixtures. Biochim Biophys Acta 1976;431:347–358.

    Article  PubMed  CAS  Google Scholar 

  30. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988;27:25–29.

    Article  PubMed  CAS  Google Scholar 

  31. Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653–662.

    Article  PubMed  CAS  Google Scholar 

  32. Patsch Jr, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Arterioscler Thromb 1992;12:1336–1345.

    Article  PubMed  CAS  Google Scholar 

  33. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. — Biol Chem 1984;259:12201–12209.

    PubMed  CAS  Google Scholar 

  34. Ohta T, Hattori S, Nishiyama S, Matsuda I. Studies on the lipid and apolipoprotein compositions of two species of apoA-I-containing lipoproteins in normolipidemic males and females. — Lipid Res 1988;29:721–728.

    PubMed  CAS  Google Scholar 

  35. Mowri HO, Patsch W, Smith LC, Gotto AM Jr, Patsch Jr. Different reactivities of high density lipoprotein subtractions with hepatic lipase. — Lipid Res 1992;33:1269–1279.

    PubMed  CAS  Google Scholar 

  36. Luc G, Parra HJ, Zylberberg G, Fruchart JC. Plasma concentrations of apolipoprotein A-I containing particles in normolipidaemic young men. Eur — Clin Invest 1991;21:118–122.

    Article  CAS  Google Scholar 

  37. Schultz Jr, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. ApoAI and apoAI — apoAII transgenic mice: — comparison of atherosclerotic susceptibility [Abstract]. Abstracts submitted to the Council on Arteriosclerosis for the 65th Scientific Sessions of the American Heart Association, November 16-19, 1992;38. Unpublished abstracts book.

    Google Scholar 

Download references

Authors
  1. A. M. Gotto Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Patsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. R. Patsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Istituto di Scienze Farmacologiche, Università di Milano, Via Balzaretti 9, I-20133, Milano, Italy

    A. L. Catapano  & Rodolfo Paoletti (Direttore) &  (Direttore)

  2. Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA

    A. M. Gotto Jr. (Chairman) (Chairman)

  3. Department of Medicine, The Methodist Hospital, 6565 Fannin M.S. A601, Houston, TX, 77030-2797, USA

    Louis C. Smith (Professor of Experimental Medicine) (Professor of Experimental Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Gotto, A.M., Patsch, W., Patsch, J.R. (1993). Experimental and Clinical Evidence for a Protective Role of High-Density Lipoprotein in Coronary Heart Disease. In: Catapano, A.L., Gotto, A.M., Smith, L.C., Paoletti, R. (eds) Drugs Affecting Lipid Metabolism. Medical Science Symposia Series, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1703-6_40

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-1703-6_40

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4746-3

  • Online ISBN: 978-94-011-1703-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation